BUSINESS
AbbVie’s Japan Sales in 2018 Double on Maviret Boon
May 23, 2019
AbbVie’s Japan revenue rocketed 104% to 172.6 billion yen in 2018, buoyed by its hepatitis C drug Maviret (glecaprevir + pibrentasvir), outperforming the double-digit growth pledged last year by country helmsman James Feliciano with an…

LATEST

May 23, 2019
A slew of new drugs joined the NHI reimbursement price list on May 22, with GlaxoSmithKline’s inhaler COPD treatment Trelegy Ellipta (fluticasone furoate + umeclidinium + vilanterol) making its Japan debut. Meanwhile, Novartis Pharma started taking orders for its CAR-T…
May 23, 2019
The Ministry of Health, Labor and Welfare (MHLW) on May 22 approved new indications and dosages for six drugs including Takeda Pharmaceutical’s inflammatory bowel disease medicine Entyvio (vedolizumab) for the treatment of Crohn’s disease (CD).Entyvio earned approval for use in…
May 23, 2019
The Japanese Medical and Dental Practitioners for the Improvement of Medical Care (Hodanren) reiterated its push for more transparency in the pricing of Novartis Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel) in a statement issued on May 22 in conjunction with…
By Yoshinori Sagehashi

As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…

By Rejii Anasako

While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA